Imatinib Completed Phase 2 Trials for Leukemias Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00006052STI571 in Treating Patients With Accelerated Phase Chronic Myelogenous Leukemia
NCT00955916CLAG Gleevec in Relapsed or Refractory Acute Myeloid Leukemia (AML)
NCT00045422Interferon Alfa and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia
NCT00769327Nilotinib and Imatinib Mesylate in Treating Patients With Early Chronic Phase Chronic Myelogenous Leukemia
NCT00110058Fludarabine and Radiation Therapy in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Chronic Phase or Accelerated Phase Chronic Myelogenous Leukemia
NCT00006475STI571 in Treating Patients With Chronic Myelogenous Leukemia in Blast Crisis
NCT01092741Late Chronic Phase Chronic Myelogenous Leukemia
NCT00618501Imatinib Mesylate and Combination Chemotherapy With or Without a Donor Stem Cell Transplant in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
NCT00006053STI571 in Treating Patients With Chronic Myelogenous Leukemia That Has Not Responded to Interferon Alfa
NCT00458848Chemotherapy With or Without Imatinib and/or Peripheral Stem Cell Transplant in Acute Lymphoblastic Leukemia
NCT00038610Study of Hyper-CVAD Plus Imatinib Mesylate for Philadelphia-Positive Acute Lymphocytic Leukemia
NCT00982488Long-term Safety of Dasatinib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia